Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease

Annals of Neurology

Volumn 48, Issue 4, 2000, Pages 567-579

  Weiner, Howard L ^a,c   Lemere, Cynthia A ^a   Maron, Ruth ^a   Spooner, Edward T ^a   Grenfell, Trelawney J ^a   Mori, Chica ^a   Issazadeh, Shohreh ^a   Hancock, Wayne W ^b   Selkoe, Dennis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CANCER GROWTH FACTOR; CYTOKINE; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 4; MYELIN BASIC PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; ASTROCYTE; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; MICE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033801852     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W     Document Type: Article

References (34)

1. Translating cell biology into therapeutic advances in Alzheimer's disease
2. The pathogenesis of senile plaques
3. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
4. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
5. Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
6. Complement activation by β-amyloid in Alzheimer disease
7. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
8. Widespread amyloid P component immunoreactivity in cortical amyloid deposits of Alzheimer's disease and other degenerative disorders
9. Clinical trial of indomethacin in Alzheimer's disease
10. Risk of Alzheimer's disease and duration of NSAID use
11. Oral tolerance: Mechanisms and therapeutic applications
12. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
13. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments
14. Inhibition of experimental autoimmune encephalomyelitis by inhalation but nor oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
15. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor
16. Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis
17. Regulatory T-cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
18. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols
19. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage
20. Inflammatory mechanisms in Alzheimer's disease
21. Inflammation and Alzheimer's disease pathogenesis
22. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
23. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease
24. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
25. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
26. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants
27. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: Implications for initial events in amyloid plaque formation
28. Amyloid β-peptide is produced by cultured cells during normal metabolism
29. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotoic genes
30. Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids
31. Temporal accrual of inflammatory proteins in the plaques of PD-APP transgenic mice between 8 and 20 months
32. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
33. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope
34. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy